SCHEMBL1386765

SCHEMBL1386765

Fc1ccc(-c2nc3[nH]ncc3c(-c3cccc(OCc4ccccc4)c3)c2-c2ccncc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.45
MAPK13 O15264 3/20 0.45
MAPK12 P53778 3/20 0.45
MAPK11 Q15759 3/20 0.45
ROCK2 O75116 1/20 0.44
GRK2 P25098 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
EGFR P00533 1/20 0.44
DYRK1B Q9Y463 2/20 0.42
CDC7 O00311 1/20 0.42
PDE4B Q07343 2/20 0.41
PTGS1 P23219 1/20 0.41
DYRK1A Q13627 1/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
PPARG P37231 1/20 0.40
KMT2A Q03164 1/20 0.40
NCOA2 Q15596 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386160 0.92 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11ROCK2
SCHEMBL1386851 0.83 MAPK14 (0.42) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL1386787 0.82 HSD17B1 (0.44) MAPK14MAPK13MAPK12MAPK11GRK2
SCHEMBL1385623 0.81 PDE10A (0.44) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2
SCHEMBL2931861 0.80 MAPK14 (0.48) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL29652689 0.80 MAPK14 (0.48) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL1386721 0.78 FGFR1 (0.45) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2
SCHEMBL1386446 0.77 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL1386881 0.77 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11
SCHEMBL1386354 0.77 PDE10A (0.39) MAPK14MAPK13MAPK12MAPK11PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
JP-4814783-B2 2011-11-16 JP claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP claimed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885MAPK13 36/4885MAPK12 38/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK13 37/4885MAPK12 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.